Stay updated on NSCLC Immunotherapy Clinical Trial

Sign up to get notified when there's something new on the NSCLC Immunotherapy Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the NSCLC Immunotherapy Clinical Trial page

  1. Check
    4 days ago
    No Change Detected
  2. Check
    10 days ago
    Change Detected
    Summary
    The page displays a 403 Forbidden error, replacing the study content with an access-denied message. This means users cannot view the trial details and related information on this page.
    Difference
    18%
    Check dated 2026-09-25T17:47:56.000Z thumbnail image
  3. Check
    17 days ago
    Change Detected
    Summary
    The page revision has been updated from v3.6.6 to v3.7.0, indicating a newer version of the page content.
    Difference
    0.0%
    Check dated 2026-09-18T18:56:16.000Z thumbnail image
  4. Check
    25 days ago
    Change Detected
    Summary
    The trial's location list was updated to drop Qiryat Krinitzi and add Tel Litwinsky in Israel, altering the set of active recruitment sites. This reflects a change in where eligible patients can enroll in the study.
    Difference
    0.0%
    Check dated 2026-09-11T16:32:05.000Z thumbnail image
  5. Check
    32 days ago
    Change Detected
    Summary
    A new site in Qiryat Krinitzi, Israel (52621) was added to the study locations, and the Tel Litwinsky, Israel (52621) site was removed, altering the enrollment options in Israel.
    Difference
    0.0%
    Check dated 2026-09-04T15:47:05.000Z thumbnail image
  6. Check
    38 days ago
    Change Detected
    Summary
    The study record now includes a funding reference: 2014 ( U.S. NIH Grant/Contract ). The page revision has been updated to v3.6.6, replacing the older v3.6.5.
    Difference
    0.0%
    Check dated 2026-08-28T17:18:15.000Z thumbnail image
  7. Check
    53 days ago
    Change Detected
    Summary
    A new PubMed citation has been added to the Publications section for the study: Nishio M, Hayashi H, Goto Y, et al. Nivolumab plus ipilimumab-based treatment in Japanese patients with metastatic non-small cell lung cancer and tumor PD-L1 < 1%: a pooled analysis. Int J Clin Oncol. 2026 Aug 11. doi: 10.1007/s10147-026-03116-w. Online ahead of print.
    Difference
    0.0%
    Check dated 2026-08-14T10:51:10.000Z thumbnail image

Stay in the know with updates to NSCLC Immunotherapy Clinical Trial

Enter your email address, and we'll notify you when there's something new on the NSCLC Immunotherapy Clinical Trial page.